An engineered E. Coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans

Science Translational Medicine

Volumn 11, Issue 475, 2019, Pages

  Kurtz, Caroline B ^a   Millet, Yves A ^a,e   Puurunen, Marja K ^a   Perreault, Mylène ^a   Charbonneau, Mark R ^a   Isabella, Vincent M ^a   Kotula, Jonathan W ^a,f   Antipov, Eugene ^a   Dagon, Yossi ^a   Denney, William S ^b   Wagner, David A ^c   West, Kip A ^a   Degar, Andrew J ^d   Brennan, Aoife M ^a   Miller, Paul F ^a  

^a SYNLOGIC   (United States)

^b Human Predictions   (United States)

^c METABOLIC SOLUTIONS INC   (United States)

^d Diversigen Inc   (United States)

^e Present Address: Kaleido Biosciences   (United States)

^f Caribou Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; AMMONIUM CHLORIDE; ARGININE; NITRATE; NITROGEN 15; ORNITHINE CARBAMOYLTRANSFERASE; PROBIOTIC AGENT; THIOACETAMIDE; UREA; NITRIC ACID DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; COLONY FORMING UNIT; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE; FEMALE; FLATULENCE; GENETIC ENGINEERING; HEADACHE; HEPATIC ENCEPHALOPATHY; HUMAN; HUMAN EXPERIMENT; HYPERAMMONEMIA; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE PAIN; INJECTION SITE SWELLING; LIVER INJURY; MACACA FASCICULARIS; MALE; MOUSE; NAUSEA; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; UPPER RESPIRATORY TRACT INFECTION; UPREGULATION; UREA CYCLE DISORDER; VOMITING; ANIMAL; BIOSYNTHESIS; BLOOD; CHEMISTRY; CLINICAL TRIAL; DISEASE MODEL; FECES; GENETICS; METABOLISM; PHYSIOLOGICAL STRESS; SURVIVAL ANALYSIS; URINE;

AMMONIA; ANIMALS; ARGININE; BIOSYNTHETIC PATHWAYS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; FECES; FEMALE; GENETIC ENGINEERING; HEALTHY VOLUNTEERS; HUMANS; HYPERAMMONEMIA; MACACA FASCICULARIS; MALE; MICE; NITRATES; STRESS, PHYSIOLOGICAL; SURVIVAL ANALYSIS;

EID: 85060169680     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aau7975     Document Type: Article

References (90)

1. D. T. Riglar, T. W. Giessen, M. Baym, S. J. Kerns, M. J. Niederhuber, R. T. Bronson, J. W. Kotula, G. K. Gerber, J. C. Way, P. A. Silver, Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation. Nat. Biotechnol. 35, 653-658 (2017).
2. M. L. Hanson, J. A. Hixon, W. Li, B. K. Felber, M. R. Anver, C. A. Stewart, B. M. Janelsins, S. K. Datta, W. Shen, M. H. McLean, S. Durum, Oral delivery of IL27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 146, 210-221.e13 (2014).
3. L. Steidler, W. Hans, L. Schotte, S. Neirynck, F. Obermeier, W. Falk, W. Fiers, E. Remaut, Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352-1355 (2000).
4. Z. Z. R. Hamady, N. Scott, M. D. Farrar, M. Wadhwa, P. Dilger, T. R. Whitehead, R. Thorpe, K. T. Holland, J. P. A. Lodge, S. R. Carding, Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-1 under the control of dietary xylan 1. Inflamm. Bowel Dis. 17, 1925-1935 (2011).
5. F. F. Duan, J. H. Liu, J. C. March, Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes 64, 1794-1803 (2015).
6. T.-C. D. Shen, L. Albenberg, K. Bittinger, C. Chehoud, Y.-Y. Chen, C. A. Judge, L. Chau, J. Ni, M. Sheng, A. Lin, B. J. Wilkins, E. L. Buza, J. D. Lewis, Y. Daikhin, I. Nissim, M. Yudkoff, F. D. Bushman, G. D. Wu, Engineering the gut microbiota to treat hyperammonemia. J. Clin. Invest. 125, 2841-2850 (2015).
7. V. M. Isabella, B. N. Ha, M. J. Castillo, D. J. Lubkowicz, S. E. Rowe, Y. A. Millet, C. L. Anderson, N. Li, A. B. Fisher, K. A. West, P. J. Reeder, M. M. Momin, C. G. Bergeron, S. E. Guilmain, P. F. Miller, C. B. Kurtz, D. Falb, Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857-864 (2018).
8. W. H. Tang, T. Kitai, S. L. Hazen, Gut microbiota in cardiovascular health and disease. Circ. Res. 120, 1183-1196 (2017).
9. K. Yamashiro, R. Tanaka, T. Urabe, Y. Ueno, Y. Yamashiro, K. Nomoto, T. Takahashi, H. Tsuji, T. Asahara, N. Hattori, Gut dysbiosis is associated with metabolism and systemic inflammation in patients with ischemic stroke. PLOS ONE 12, e0171521 (2017).
10. M. Imler, G. Chabrier, C. Simon, J. L. Schlienger, Intestinal ammonium production in the rat: The role of the colon, small intestine, and circulating glutamine. Res. Exp. Med. 188, 1-7 (1988).
11. E. A. Phear, B. Ruebner, The in vitro production of ammonium and amines by intestinal bacteria in relation to nitrogen toxicity as a factor in hepatic coma. Br. J. Exp. Pathol. 37, 253-262 (1956).
12. E. Wolpert, S. F. Phillips, W. H. J. Summerskill, Transport of urea and ammonia production in the human colon. Lancet 298, 1387-1390 (1971).
13. E. B. Tapper, Z. G. Jiang, V. R. Patwardhan, Refining the ammonia hypothesis: A physiology-driven approach to the treatment of hepatic encephalopathy. Mayo Clin. Proc. 90, 646-658 (2015).
14. J. T. Brosnan, Interorgan amino acid transport and its regulation. J. Nutr. 133, 2068S-2072S (2003).
15. H. G. Windmueller, A. E. Spaeth, Uptake and metabolism of plasma glutamine by the small intestine. J. Biol. Chem. 249, 5070-5079 (1974).
16. M. Walser, L. J. Bodenlos, Urea metabolism in man. J. Clin. Invest. 38, 1617-1626 (1959).
17. H. L. Mobley, R. P. Hausinger, Microbial ureases: Significance, regulation, and molecular characterization. Microbiol. Rev. 53, 85-108 (1989).
18. D. Häussinger, B. Stoll, T. Stehle, W. Gerok, Hepatocyte heterogeneity in glutamate metabolism and bidirectional transport in perfused rat liver. Eur. J. Biochem. 185, 189-195 (1989).
19. D. Häussinger, W. Gerok, Hepatocyte heterogeneity in glutamate uptake by isolated perfused rat liver. Eur. J. Biochem. 136, 421-425 (1983).
20. S. W. M. Olde Damink, R. Jalan, C. H. C. Dejong, Interorgan ammonia trafficking in liver disease. Metab. Brain Dis. 24, 169-181 (2009).
21. J. V. Leonard, A. A. M. Morris, Urea cycle disorders. Semin. Neonatol. 7, 27-35 (2002).
22. D. R. Aldridge, E. J. Tranah, D. L. Shawcross, Pathogenesis of hepatic encephalopathy: Role of ammonia and systemic inflammation. J. Clin. Exp. Hepatol. 5, S7-S20 (2015).
23. D. Suraweera, V. Sundaram, S. Saab, Evaluation and management of hepatic encephalopathy: Current status and future directions. Gut Liver 10, 509-519 (2016).
24. H. Vilstrup, P. Amodio, J. Bajaj, J. Cordoba, P. Ferenci, K. D. Mullen, K. Weissenborn, P. Wong, Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the study of liver diseases and the European Association for the study of the liver. Hepatology 60, 715-735 (2014).
25. S. Scaglione, S. Kliethermes, G. Cao, D. Shoham, R. Durazo, A. Luke, M. L. Volk, The epidemiology of cirrhosis in the United States: A population-based study. J. Clin. Gastroenterol. 49, 690-696 (2015).
26. Y. Kim, A. Ejaz, A. Tayal, G. Spolverato, J. F. P. Bridges, R. A. Anders, T. M. Pawlik, Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer 120, 3058-3065 (2014).
27. K. R. Patidar, J. S. Baja, Covert and overt hepatic encephalopathy: Diagnosis and management. Clin. Gastroenterol. Hepatol. 13, 2048-2061 (2015).
28. J. O. Clemmesen, F. S. Larsen, J. Kondrup, B. A. Hansen, P. Ott, Cerebral herniation in patients with acute E liver failure is correlated with arterial ammonia concentration. Hepatology 29, 648-653 (1999).
29. P. S. Ge, B. A. Runyon, Serum ammonia level for the evaluation of hepatic encephalopathy. JAMA 312, 643-644 (2014).
30. J. P. Ong, A. Aggarwal, D. Krieger, K. A. Easley, M. T. Karafa, F. Van Lente, A. C. Arroliga, K. D. Mullen, Correlation between ammonia levels and the severity of hepatic encephalopathy. Am. J. Med. 114, 188-193 (2003).
31. A. M. Dawson, J. McLaren, S. Sherlock, Neomycin in the treatment of hepatic coma. Lancet 273, 1262-1268 (1957).
32. B. B. Fast, S. J. Wolfe, J. M. Stormont, C. S. Davidson, Antibiotic therapy in the management of hepatic coma. A.M.A. Arch. Intern. Med. 101, 467-475 (1958).
33. C. L. H. van Berlo, P. A. M. van Leeuwen, P. B. Soeters, Porcine intestinal ammonia liberation: Influence of food intake, lactulose, and neomycin treatment. J. Hepatol. 7, 250-257 (1988).
34. N. M. Bass, K. D. Mullen, A. Sanyal, F. Poordad, G. Neff, C. B. Leevy, S. Sigal, M. Y. Sheikh, K. Beavers, T. Frederick, L. Teperman, D. Hillebrand, S. Huang, K. Merchant, A. Shaw, E. Bortey, W. P. Forbes, Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 362, 1071-1081 (2010).
35. C. R. Bosoi, C. Parent-Robitaille, K. Anderson, M. Tremblay, C. F. Rose, AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct-ligated rats. Hepatology 53, 1995-2002 (2011).
36. B. S. Rajagopal, J. DePonte III, M. Tuchman, M. H. Malamy, Use of inducible feedback-resistant N-acetylglutamate synthetase (argA) genes for enhanced arginine biosynthesis by genetically engineered Escherichia coli K-12 strains. Appl. Environ. Microbiol. 64, 1805-1811 (1998).
37. G. Neff, Factors affecting compliance and persistence with treatment for hepatic encephalopathy. Pharmacotherapy 30, 22S-27S (2010).
38. S. L. Flamm, Considerations for the cost-effective management of hepatic encephalopathy. Am. J. Manag. Care 24, S51-S61 (2018).
39. T. M. Wassenaar, Insights from 100 years of research with probiotic E. coli. Eur. J. Microbiol. Immunol. 6, 147-161 (2016).
40. C. Kurtz, W. S. Denney, L. Blankstein, S. E. Guilmain, S. Machinani, J. Kotula, S. Saha, P. Miller, A. M. Brennan, Translational development of microbiome-based therapeutics: Kinetics of E. coli Nissle and engineered strains in humans and nonhuman primates. Clin. Transl. Sci. 11, 200-207 (2018).
41. W. Kruis, E. Schütz, P. Fric, B. Fixa, G. Judmaier, M. Stolte, Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 11, 853-858 (1997).
42. W. Kruis, P. Frič, J. Pokrotnieks, M. Lukás, B. Fixa, M. Kaščák, M. A. Kamm, J. Weismueller, C. Beglinger, M. Stolte, C. Wolff, J. Schulze, Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53, 1617-1623 (2004).
43. B. J. Rembacken, A. M. Snelling, P. M. Hawkey, D. M. Chalmers, A. T. R. Axon, Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 354, 635-639 (1999).
44. W. Kruis, S. Chrubasik, S. Boehm, C. Stange, J. Schulze, A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int. J. Colorectal Dis. 27, 467-474 (2012).
45. J. Häberle, N. Boddaert, A. Burlina, A. Chakrapani, M. Dixon, M. Huemer, D. Karall, D. Martinelli, P. S. Crespo, R. Santer, A. Servais, V. Valayannopoulos, M. Lindner, V. Rubio, C. Dionisi-Vici, Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J. Rare Dis. 7, 32 (2012).
46. C. J. McNeal, C. J. Meininger, D. Reddy, C. D. Wilborn, G. Wu, Safety and effectiveness of arginine in adults. J. Nutr. 146, 2587S-2593S (2016).
47. E. Sancho-Vaello, M. L. Fernandez-Murga, V. Rubio, Mechanism of arginine regulation of acetylglutamate synthase, the first enzyme of arginine synthesis. FEBS Lett. 583, 202-206 (2009).
48. G. Zhao, Z. Jin, N. M. Allewell, M. Tuchman, D. Shi, Crystal structure of the N-acetyltransferase domain of human N-acetyl-L-glutamate synthase in complex with N-acetyl-L-glutamate provides insights into its catalytic and regulatory mechanisms. PLOS ONE 8, e70369 (2013).
49. S. Durand, G. Storz, Reprogramming of anaerobic metabolism by the FnrS small RNA. Mol. Microbiol. 75, 1215-1231 (2010).
50. A. Boysen, J. Møller-Jensen, B. Kallipolitis, P. Valentin-Hansen, M. Overgaard, Translational regulation of gene expression by an anaerobically induced small non-coding RNA in Escherichia coli. J. Biol. Chem. 285, 10690-10702 (2010).
51. S. I. Ahmad, S. H. Kirk, A. Eisenstark, Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu. Rev. Microbiol. 52, 591-625 (1998).
52. U.S. Department of Health and Human Services, Food and Drug Administration Guidance for Industry, “Early clinical trials with live biotherapeutic products: Chemistry, manufacturing, and control information,” February 2012; www.fda.gov/downloads/Biologi%E2%80%A6/UCM292704.pdf [updated June 2016].
53. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
54. M. Fulde, J. Willenborg, A. de Greeff, L. Benga, H. E. Smith, P. Valentin-Weigand, R. Goethe, ArgR is an essential local transcriptional regulator of the arcABC operon in Streptococcus suis and is crucial for biological fitness in an acidic environment. Microbiology 157, 572-582 (2011).
55. C.-D. Lu, H. Winteler, A. Abdelal, D. Haas, The ArgR regulatory protein, a helper to the anaerobic regulator ANR during transcriptional activation of the arcD promoter in Pseudomonas aeruginosa. J. Bacteriol. 181, 2459-2464 (1999).
56. A. Battesti, N. Majdalani, S. Gottesman, The RpoS-mediated general stress response in Escherichia coli. Annu. Rev. Microbiol. 65, 189-213 (2011).
57. F. Arsène, T. Tomoyasu, B. Bukau, The heat shock response of Escerichia coli. Int. J. Food Microbiol. 55, 3-9 (2000).
58. M.-P. Castanié-Cornet, K. Cam, B. Bastiat, A. Cros, P. Bordes, C. Gutierrez, Acid stress response in Escherichia coli: Mechanism of regulation of gadA transcription by RcsB and GadE. Nucleic Acids Res. 38, 3546-3554 (2010).
59. Y. C. Luiking, N. E. P. Deutz, Biomarkers of arginine and lysine excess. J. Nutr. 137, 1662S-1668S (2007).
60. ash mouse: A missense mutation in the ornithine transcarbamylase gene also causes aberrant mRNA splicing. Proc. Natl. Acad. Sci. U.S.A. 86, 4142-4146 (1989).
61. D. T. Riglar, P. A. Silver, Engineering bacteria for diagnostic and therapeutic applications. Nat. Rev. Microbiol. 16, 214-225 (2018).
62. H. Braat, P. Rottiers, D. W. Hommes, N. Huyghebaert, E. Remaut, J.-P. Remon, S. J. H. van Deventer, S. Neirynck, M. P. Peppelenbosch, L. Steidler, A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4, 754-759 (2006).
63. S. A. Limaye, R. I. Haddad, F. Cilli, S. T. Sonis, A. D. Colevas, M. T. Brennan, K. S. Hu, B. A. Murphy, Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 119, 4268-4276 (2013).
64. E. G. Pamer, Immune responses to Listeria monocytogenes. Nat. Rev. Immunol. 4, 812-823 (2004).
65. R. Okazaki, A. Kornberg, Deoxythymidine kinase of Escherichia coli. I. Purification and some properties of the enzyme. J. Biol. Chem. 239, 269-274 (1964).
66. B. A. McCullough, M. Yudkoff, M. L. Batshaw, J. M. Wilson, S. E. Raper, M. Tuchman, Genotype spectrum of ornithine transcarbamylase deficiency: Correlation with the clinical and biochemical phenotype. Am. J. Med. Genet. 93, 313-319 (2000).
67. A. L. Gropman, M. Summar, J. V. Leonard, Neurological implications of urea cycle disorders. J. Inherit. Metab. Dis. 30, 865-879 (2007).
68. B. Parmeggiani, C. R. Vargas, Oxidative stress in urea cycle disorders: Findings from clinical and basic research. Clin. Chim. Acta 477, 121-126 (2018).
69. R. F. Butterworth, M. D. Norenberg, V. Felipo, P. Ferenci, J. Albrecht, A. T. Blei, Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int. 29, 783-788 (2009).
70. R. K. Dhiman, B. Rana, S. Agrawal, A. Garg, M. Chopra, K. K. Thumburu, A. Khattri, S. Malhotra, A. Duseja, Y. K. Chawla, Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: A randomized, controlled trial. Gastroenterology 147, 1327-1337.e3 (2014).
71. S. Wang, M. Xu, W. Wang, X. Cao, M. Piao, S. Khan, F. Yan, H. Cao, B. Wang, Systematic review: Adverse events of fecal microbiota transplantation. PLOS ONE 11, e0161174 (2016).
72. U. Sonnenborn, J. Schulze, The non-pathogenic Escherichia coli strain Nissle 1917-Features of a versatile probiotic. Microb. Ecol. Health Dis. 21, 122-158 (2009).
73. E. van Nood, A. Vrieze, M. Nieuwdorp, S. Fuentes, E. G. Zoetendal, W. M. de Vos, C. E. Visser, E. J. Kuijper, J. F. W. M. Bartelsman, J. G. P. Tijssen, P. Speelman, M. G. W. Dijkgraaf, J. J. Keller, Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407-415 (2013).
74. Q. Liu, Z. P. Duan, D. K. Ha, S. Bengmark, J. Kurtovic, S. M. Riordan, Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39, 1441-1449 (2004).
75. A. A. Zyrek, C. Cichon, S. Helms, C. Enders, U. Sonnenborn, M. A. Schmidt, Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKC redistribution resulting in tight junction and epithelial barrier repair. Cell. Microbiol. 9, 804-816 (2007).
76. Y. Dagon, Y. Millet, L. Renaud, B. Ha, D. Wong, M. Castillo, J. Thomas, J. Lora, P. Miller, C. Kurtz, Genetically engineered E. coli Nissle attenuates hyperammonemia in a mouse model of hepatic encephalopathy by metabolizing gut ammonia and increasing urea production. Gastroenterology 154, S-1078 (2018).
77. S. M. Morris Jr., Arginine metabolism revisited. J. Nutr. 146, 2579S-2586S (2016).
78. F. Mariotti, K. J. Petzke, D. Bonnet, I. Szezepanski, C. Bos, J.-F. Huneau, H. Fouillet, Kinetics of the utilization of dietary arginine for nitric oxide and urea synthesis: Insight into the arginine-nitric oxide metabolic system in humans. Am. J. Clin. Nutr. 97, 972-979 (2013).
79. C. D. Leaf, J. S. Wishnok, S. R. Tannenbaum, L-arginine is a precursor for nitrate biosynthesis in humans. Biochem. Biophys. Res. Commun. 163, 1032-1037 (1989).
80. L. Castillo, T. C. deRojas, T. E. Chapman, J. Vogt, J. F. Burke, S. R. Tannenbaum, V. R. Young, Splanchnic metabolism of dietary arginine in relation to nitric oxide synthesis in normal adult man. Proc. Natl. Acad. Sci. U.S.A. 90, 193-197 (1993).
81. J. A. Sawitzke, L. C. Thomason, N. Costantino, M. Bubunenko, S. Datta, D. L. Court, Recombineering: In vivo genetic engineering in E. coli, S. enterica, and beyond. Methods Enzymol. 421, 171-199 (2007).
82. M. K. Thomason, T. Bischler, S. K. Eisenbart, K. U. Förstner, A. Zhang, A. Herbig, K. Nieselt, C. M. Sharma, G. Storz, Global transcriptional start site mapping using differential RNA sequencing reveals novel antisense RNAs in Escherichia coli. J. Bacteriol. 197, 18-28 (2015).
83. M. R. Charbonneau, D. O'Donnell, L. V. Blanton, S. M. Totten, J. C. C. Davis, M. J. Barratt, J. Cheng, J. Guruge, M. Talcott, J. R. Bain, M. J. Muehlbauer, O. Ilkayeva, C. Wu, T. Struckmeyer, D. Barile, C. Mangani, J. Jorgensen, Y.-m. Fan, K. Maleta, K. G. Dewey, P. Ashorn, C. B. Newgard, C. Lebrilla, D. A. Mills, J. I. Gordon, Sialylated milk oligosaccharides promote microbiota-dependent growth in models of infant undernutrition. Cell 164, 859-871 (2016).
84. A. M. Bolger, M. Lohse, B. Usadel, Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114-2120 (2014).
85. M. Reister, K. Hoffmeier, N. Krezdorn, B. Rotter, C. Liang, S. Rund, T. Dandekar, U. Sonnenborn, T. A. Oelschlaeger, Complete genome sequence of the Gram-negative probiotic Escherichia coli strain Nissle 1917. J. Biotechnol. 187, 106-107 (2014).
86. B. Langmead, C. Trapnell, M. Pop, S. L. Salzberg, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
87. S. Anders, P. T. Pyl, W. Huber, HTSeq-A Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166-169 (2015).
88. M. Kanehisa, Y. Sato, M. Kawashima, M. Furumichi, M. Tanabe, KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44, D457-D462 (2016).
89. M. C. Wallace, K. Hamesch, M. Lunova, Y. Kim, R. Weiskirchen, P. Strnad, S. L. Friedman, Standard operating procedures in experimental liver research: Thioacetamide model in mice and rats. Lab. Anim 49, 21-29 (2015).
90. M. Yudkoff, Y. Daikhin, I. Nissim, A. Jawad, J. Wilson, M. Batshaw, In vivo nitrogen metabolism in ornithine transcarbamylase deficiency. J. Clin. Invest. 98, 2167-2173 (1996).